Pfizer Inc. posted successful topline results from the Phase III BASIS study of marstacimab in hemophilia A and B, but it remains unclear how competitive it will be on the market once approved, particularly in hemophilia A, where Sanofi’s Altuviiio (efanesoctocog alfa) won US Food and Drug Administration approval just months ago and Roche Holding AG’s Hemlibra (emicizumab) has dominated since its approval in 2017.
While one analyst was cautiously optimistic about the lack of clotting events – historically an issue with drugs that target anticoagulation, as marstacimab does – it will